Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Section 32 Fund 2, LP — Fulcrum Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Section 32 Fund 2, LP

Section 32 Fund 2, LP

10% owner at Fulcrum Therapeutics, Inc. · on record since Jul 22, 2019
10% owner at EMDEON CORP · on record since Sep 30, 2021

Insider trading activity of Section 32 Fund 2, LP

Transactions on record: 2; since Jul 22, 2019

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Jul 22, 2019

Figures computed from official regulatory filings — methodology.

Companies where Section 32 Fund 2, LP has traded

Fulcrum Therapeutics, Inc.2 tx · Jul 22, 2019

Track record of Section 32 Fund 2, LP

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Section 32 Fund 2, LP

Co-insiders of Section 32 Fund 2, LP

Maris William JEMDEON CORP +1
Section 32 GP 2, LLCEMDEON CORP +1
6 Dimensions Capital, L.P.Fulcrum Therapeutics, Inc.
Achar Christopher KEMDEON CORP
ADLER MARK J MDEMDEON CORP
Arroyo SantiagoFulcrum Therapeutics, Inc.
Badlani NeilEMDEON CORP

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Banks SonjaFulcrum Therapeutics, Inc.

Bradford K JoanneEMDEON CORP

BROOKE PAUL AEMDEON CORP

Cadavid DiegoFulcrum Therapeutics, Inc.

CalPERS/PCG Corporate Partners, LLCEMDEON CORP

Cameron Kevin MEMDEON CORP

Casdin Capital, LLCFulcrum Therapeutics, Inc.

Casdin EliFulcrum Therapeutics, Inc.

Casdin Partners GP, LLCFulcrum Therapeutics, Inc.

Casdin Partners Master Fund, L.P.Fulcrum Therapeutics, Inc.

CHEN ANDY KUANGEMDEON CORP

Collins James J.Fulcrum Therapeutics, Inc.

CORBIN ANDREW CEMDEON CORP

Cove Investors II, LLCEMDEON CORP

Cove Investors I, LLCEMDEON CORP

CP (HLTH), LLCEMDEON CORP

Cui XiangminEMDEON CORP

Day Kelly P.EMDEON CORP

Decheng Capital China Life Sciences USD Fund III, L.P.EMDEON CORP

Decheng Capital Management III (Cayman), LLCEMDEON CORP

DIMICK NEIL FEMDEON CORP

Dorton KatinaFulcrum Therapeutics, Inc.

DRAUGHON K ROBERTEMDEON CORP

Dunn JudithFulcrum Therapeutics, Inc.

Efird KennethEMDEON CORP

Ezekowitz AlanFulcrum Therapeutics, Inc.

Faig Carole TEMDEON CORP

FLEMING HARRY JOSEPHEMDEON CORP

Foster Thomas Orion IIIEMDEON CORP

FUNSTON MARK DEMDEON CORP

Gallagher John EEMDEON CORP

Gang David AEMDEON CORP

GANLEY RICHARDEMDEON CORP

GATTINELLA WAYNE TEMDEON CORP

GERAGHTY JAMES AFulcrum Therapeutics, Inc.

Ghaim JoshuaEMDEON CORP

GLAXOSMITHKLINE PLCFulcrum Therapeutics, Inc.

Gould Robert JFulcrum Therapeutics, Inc.

HAUSER JENNIFEREMDEON CORP

Haviland KateFulcrum Therapeutics, Inc.

Hayes Melvin H. IIIFulcrum Therapeutics, Inc.

Hill ColinFulcrum Therapeutics, Inc.

HOLCOMBE TONY GEMDEON CORP

Company	Filed	Type	Qty	Price	Value · USD	Src
Fulcrum Therapeutics, Inc.	Jul 22, 2019	Other	464,285	—	—	SEC
Fulcrum Therapeutics, Inc.	Jul 22, 2019	OtherD	-3,250,000	0.00 USD	$0	SEC